Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Molecular mechanisms of sorafenib action in liver cancer cells.

Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G.

Cell Cycle. 2012 Aug 1;11(15):2843-55. doi: 10.4161/cc.21193. Epub 2012 Aug 1.

PMID:
22801548
2.

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, Spencer S, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Gordon MS.

Clin Cancer Res. 2012 Sep 1;18(17):4820-9. doi: 10.1158/1078-0432.CCR-12-0098. Epub 2012 Jul 5.

3.

Identification of differential gene expression profiles in placentas from preeclamptic pregnancies versus normal pregnancies by DNA microarrays.

Meng T, Chen H, Sun M, Wang H, Zhao G, Wang X.

OMICS. 2012 Jun;16(6):301-11. doi: 10.1089/omi.2011.0066.

4.

Selective blockade of tumor angiogenesis.

Chaudhary A, St Croix B.

Cell Cycle. 2012 Jun 15;11(12):2253-9. doi: 10.4161/cc.20374. Epub 2012 Jun 15.

5.

Roles of BCL6 in normal and transformed germinal center B cells.

Basso K, Dalla-Favera R.

Immunol Rev. 2012 May;247(1):172-83. doi: 10.1111/j.1600-065X.2012.01112.x. Review.

PMID:
22500840
6.

Microarray screening for novel preeclampsia biomarker candidates.

Lapaire O, Grill S, Lalevee S, Kolla V, Hösli I, Hahn S.

Fetal Diagn Ther. 2012;31(3):147-53. doi: 10.1159/000337325. Epub 2012 Mar 29.

7.

Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.

Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B, Joven J, Menendez JA.

Cell Cycle. 2012 Mar 1;11(5):865-70. doi: 10.4161/cc.11.5.19252. Epub 2012 Mar 1.

PMID:
22333588
8.

Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation.

Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G.

Oncotarget. 2011 Dec;2(12):1191-202.

9.

Analyses of placental gene expression in pregnancy-related hypertensive disorders.

Chang SD, Chao AS, Peng HH, Chang YL, Wang CN, Cheng PJ, Lee YS, Chao A, Wang TH.

Taiwan J Obstet Gynecol. 2011 Sep;50(3):283-91. doi: 10.1016/j.tjog.2011.07.005.

10.

IFPA Award in Placentology lecture: molecular regulation of human trophoblast invasion.

Knöfler M, Pollheimer J.

Placenta. 2012 Feb;33 Suppl:S55-62. doi: 10.1016/j.placenta.2011.09.019. Epub 2011 Oct 21.

11.

Gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis-related genes ACVRL1 and EGFL7 in early-onset disease.

Junus K, Centlow M, Wikström AK, Larsson I, Hansson SR, Olovsson M.

Mol Hum Reprod. 2012 Mar;18(3):146-55. doi: 10.1093/molehr/gar067. Epub 2011 Oct 19.

12.

Glycodelin-A protein interacts with Siglec-6 protein to suppress trophoblast invasiveness by down-regulating extracellular signal-regulated kinase (ERK)/c-Jun signaling pathway.

Lam KK, Chiu PC, Lee CL, Pang RT, Leung CO, Koistinen H, Seppala M, Ho PC, Yeung WS.

J Biol Chem. 2011 Oct 28;286(43):37118-27. doi: 10.1074/jbc.M111.233841. Epub 2011 Aug 31.

13.

Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer.

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Clin Cancer Res. 2011 Oct 1;17(19):6272-86. doi: 10.1158/1078-0432.CCR-11-0060. Epub 2011 Aug 17.

14.

Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia.

Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T.

Circulation. 2011 Aug 23;124(8):940-50. doi: 10.1161/CIRCULATIONAHA.111.034793. Epub 2011 Aug 1.

15.

Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction.

Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, Udagawa Y.

Reprod Biol Endocrinol. 2011 Aug 2;9:107. doi: 10.1186/1477-7827-9-107.

16.

Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.

Nassiri F, Cusimano MD, Scheithauer BW, Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K, Lloyd RV.

Anticancer Res. 2011 Jun;31(6):2283-90. Review.

PMID:
21737653
17.

Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.

Shibuya M.

Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(4):167-78.

18.

Placental and maternal serum inhibin A in patients with preeclampsia and small-for-gestational-age.

Shen Z, Cai LY, Suprapto IS, Shenoy P, Zhou X.

J Obstet Gynaecol Res. 2011 Oct;37(10):1290-6. doi: 10.1111/j.1447-0756.2010.01513.x. Epub 2011 May 3.

PMID:
21535305
19.

The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α.

Demidenko ZN, Blagosklonny MV.

Cell Cycle. 2011 May 15;10(10):1557-62. Epub 2011 May 15.

PMID:
21521942
20.

Soluble Flt-1 and PlGF: new markers of early pregnancy loss?

Muttukrishna S, Swer M, Suri S, Jamil A, Calleja-Agius J, Gangooly S, Ludlow H, Jurkovic D, Jauniaux E.

PLoS One. 2011 Mar 23;6(3):e18041. doi: 10.1371/journal.pone.0018041.

Supplemental Content

Support Center